MERCK & CO Aktie

 

First presentation for MK-1045, a novel CD19xCD3 T-cell engager in patients with certain types of leukemia and lymphoma, and for bomedemstat, an LSD1 inhibitor, in patients with polycythemia vera New data demonstrate continued progress with nemtabrutinib, an investigational non-covalent BTK inhibitor RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to advancing clinical research in hematology across Merck's expanding and diverse pipeline of investigational candidates, with more than 20 abstracts being presented. “The data we're sharing at ASH 2025 reflect the continued growth and evolution of our promising hematology pipeline,” said Dr. Gregory Lubiniecki, vice pre...

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) has been notified that Tutanota LLC has commenced an unsolicited mini-tender offer, dated November 10, 2025, to purchase up to 1 million shares of......

Wien (www.aktiencheck.de) - Merck-Aktienanalyse von der Raiffeisen Bank International AG: Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), rät in einer aktuellen Aktienanalyse die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) weiterhin zu kaufen. [mehr]...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda....

MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up....

Der positive Newsflow bei der amerikanischen Merck & Co reißt nicht ab. Nach äußerst vielversprechenden Studiendaten am Dienstag legt das Unternehmen mit einer weiteren Zulassung und frischen Ergebnissen zu einer HIV-Therapie nach. Bei der im Dow Jones gelisteten Aktie zeichnen sich weitere Kursgewinne ab....

Nach einer Phase voller Negativschlagzeilen zeigt Merck & Co. plötzlich wieder Stärke – und das aus gutem Grund....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every d...

Mit einem Kursplus von rund 3,5 Prozent setzt sich die Aktie von Merck & Co in einem schwachen Gesamtmarkt an die Spitze im US-amerikanischen Leitindex Dow Jones. Frische Studiendaten verhelfen dem defensiven Titel zu einem erneuten Kurssprung – und die milliardenschwere Übernahme von Acceleron Pharma zahlt sich weiter aus....

Charlotte (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Bank of America (BofA): BofA-Analyst Tim Anderson habe das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 98 auf 105 USD angehoben und das "buy"-Rating bestätigt. Der Deal mit Cidara werde als vernünftig bezeichnet, da das experimentelle Grippemittel des Unternehmens ein neuartiges Asset mit hoher technischer Erfolgschance darstelle und zudem gut zu Mercks Infektionskrankheiten-Portfolio passe, Zudem sei die Merck-Aktie, angesichts des Wachstums, das der US-Pharmakonzern kurz- wie langfristig liefern dürfte, aktuell zu günstig bewertet, heiße es in einer aktuellen Research Note. [mehr]...

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves....

Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum....

Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve's CloakLink™ linker technology Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, and all existing investorsSAN DIEGO--(BUSINESS WIRE)--#ADC--Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, today announced it has raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform. The round was led by Yosemite, with participation from Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., and SymBiosis, and existing investors Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic, and Surveyor Capital (a Citadel company). This lat...

Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda. Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday's closing price, for a total transaction value of about $9.2 billion, the companies said Friday in a statement.  Bloomberg's Madison Muller joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Der Medienbericht der Financial Times (FT), wonach Merck & Co vor der Übernahme von Cidara Therapeutics steht, wurde bestätigt. Der US-Pharma-Konzern zahlt gut neun Milliarden Dollar für die Biotech-Gesellschaft, die einen hochinteressanten potenziellen Prophylaxe-Wirkstoff gegen Influenza A und B (Grippe) verfügt..

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per s......

Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda....

RAHWAY/SAN DIEGO (dpa-AFX) - Der US-Pharmakonzern Merck & Co (Merck) will mit einer Milliardenübernahme sein Geschäft mit antiviralen Medikamenten stärken. Man habe sich mit Cidara ......

Nach der erfolgreichen milliardenschweren Übernahme von Verona Pharma scheint sich der US-amerikanische Pharma-Riese Merck & Co das nächste größere Akquisitionsziel ausgeschaut zu haben. Laut einem Bericht der Financial Times (FT) zufolge hat das Unternehmen ein Auge auf Cidara Therapeutics geworfen....